Scientific Reports · 2018 · 61 citations · 21 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyMonoclonal AntibodiesCancer ImmunotherapyChimeric Antigen Receptor T-cell TherapyMonoclonal Antibody TechnologyMonoclonal Antibody TherapyTargeted Cancer TherapyTherapeutic Monoclonal AntibodiesAxl Receptor Tyrosine KinaseAxl SignalingHumanized Monoclonal AntibodiesMonoclonal Antibodies In CancerMonoclonal Antibodies In OncologySingle-chain Variable Fragment ConstructionSingle-chain Variable FragmentsSynthetic Receptor Engineering
Axl is a tyrosine kinase receptor that is commonly overexpressed in many cancers. As such, Axl represents an attractive therapeutic target. The transfer of engineered T cell expressing chimeric antigen receptor (CAR) is an exciting cancer therapeutic approach that shows high efficacy against cancers in clinical trials, especially for B cell malignancies. Furthermore, recently developed synthetic Notch (synNotch) receptor has demonstrated potential in enhancing the specificity of CAR T cell therapy and delivering therapeutic payloads to tumors in an antigen-dependent manner. Therefore, a CAR or synNotch against Axl could be a valuable therapeutic reagent against many cancers. Here, we develop a single-chain variable fragment from a humanized monoclonal antibody against Axl. The scFv is attached to CD3ζ, CD28, and 4-1BB signaling domains to generate an anti-Axl CAR. When introduced into human primary T cells, the anti-Axl CAR can lead to cytokine production and cell killing in response to tumor cells expressing Axl. Moreover, an anti-Axl synNotch generated using the same scFv can be activated with Axl expressing tumor cells. Given the fact that Axl is an important cancer therapeutic target, these receptors could be valuable reagents for developing anti-Axl therapies.
21
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude, Noelle V. Frey, Pamela A. Shaw et al. · New England Journal of Medicine · 2014 · 5.4K citations · Full text
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp, Michael Kalos, David M. Barrett et al. · New England Journal of Medicine · 2013 · 3.5K citations · Full text
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang, Jae Cheol Lee, Luping Lin et al. · Nature Genetics · 2012 · 1.2K citations
Medicine, Cancer Biology, Oncology +16